Bionano Genomics to Report Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
July 28 2022 - 4:01PM
Bionano Genomics, Inc. (BNGO) today announced that it will
host a conference call and live webcast on Thursday, August 4th,
2022 at 4:30 p.m. Eastern Time to report financial results for the
second quarter 2022 and to highlight recent corporate progress.
Conference Call & Webcast Details |
Date: |
Thursday,
August 4, 2022 |
Time: |
4:30 p.m. Eastern Time |
Live Call: |
Register here for dial-in number and pin |
Live Webcast: |
https://edge.media-server.com/mmc/p/tm6m746p |
Participants may access a live webcast of the call on the
Investors page of the Bionano website. To participate via
telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay of the
conference call and webcast will be archived on Bionano’s investor
relations website at https://ir.bionanogenomics.com/ for at least
30 days.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions
that can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
optical genome mapping (OGM) solutions, diagnostic services and
software. The Company offers OGM solutions for applications across
basic, translational and clinical research. Through
its Lineagen business, the Company also provides
diagnostic testing for patients with clinical presentations
consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information,
visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com
CONTACTSCompany Contact:Erik Holmlin,
CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024